750334
Last Update Posted: 2015-05-21
Recruiting has ended
All Genders accepted | 18 Years + |
2 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.
Eligibility
Relevant conditions:
Myelodysplastic Syndromes
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov